Creo Medical Group (LON:CREO) Trading Down 1.8% – Here’s What Happened

Creo Medical Group PLC (LON:CREO)’s stock price dropped 1.8% on Thursday . The stock traded as low as GBX 13.50 and last traded at GBX 13.50. Approximately 2,707,456 shares traded hands during trading, an increase of 209% from the average session volume of 875,276 shares. The stock had previously closed at GBX 13.75.

Analysts Set New Price Targets

Separately, Shore Capital Group reiterated a “house stock” rating and issued a GBX 40 price target on shares of Creo Medical Group in a research report on Tuesday, May 26th.

Creo Medical Group Stock Performance

The stock has a market cap of £65.58 million, a P/E ratio of 13.50 and a beta of 1.62. The company has a quick ratio of 2.19, a current ratio of 3.22 and a debt-to-equity ratio of 8.20. The business has a 50 day moving average price of GBX 12.76 and a two-hundred day moving average price of GBX 12.61.

Creo Medical Group (LON:CREO) last issued its earnings results on Friday, May 22nd. The company reported GBX (0.04) earnings per share (EPS) for the quarter. Creo Medical Group had a net margin of 88.33% and a return on equity of 9.56%. The business had revenue of GBX 600 million for the quarter. On average, sell-side analysts forecast that Creo Medical Group PLC will post -10.0800005 earnings per share for the current fiscal year.

About Creo Medical Group

Creo Medical is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.

The Company’s vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA powered by Kamaptive full-spectrum adaptive technology to optimise surgical capability and patient outcomes.